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Abstract
Background: RSV is recognized as the most important cause of serious lower respiratory tract
illness in infants and young children worldwide leading to hospitalisation in a great number of cases,
especially in certain high-risk groups. The aims of the present study were to identify risk groups,
outcome and incidences of hospitalisation for RSV bronchiolitis in Norwegian children under two
years of age and to compare the results with other studies.
Methods: We performed a population-based retrospective survey for the period 1993–2000 in
children under two years of age hospitalised for RSV bronchiolitis.
Results: 822 admissions from 764 patients were identified, 93% had one hospitalisation, while 7%
had two or more hospitalisations. Mean annual hospitalisation incidences were 21.7 per 1.000
children under one year of age, 6.8 per 1.000 children at 1–2 years of age and 14.1 per 1.000
children under two years of age. 77 children (85 admissions) belonged to one or more high-risk
groups such as preterm birth, trisomy 21 and congenital heart disease. For preterm children under
one year of age, at 1–2 years of age and under two years of age hospitalisation incidences per 1.000
children were 23.5, 8.7 and 16.2 respectively. The incidence for children under two years of age
with trisomy 21 was 153.8 per 1.000 children.
Conclusion: While the overall hospitalisation incidences and outcome of RSV bronchiolitis were
in agreement with other studies, hospitalisation incidences for preterm children were lower than
in many other studies. Age on admission for preterm children, when corrected for prematurity,
was comparable to low-risk children. Length of hospitalisation and morbidity was high in both
preterm children, children with a congenital heart disease and in children with trisomy 21, the last
group being at particular high risk for severe disease.
Background
Respiratory tract infections due to respiratory syncytial
virus (RSV) are very common in young children world-
wide. In temperate climates the infection occurs in yearly
winter epidemics, and by two years of age most children
have been infected [1]. Reinfections are common
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severe [2]. Symptoms vary from a mild upper respiratory
tract infection to a severe bronchiolitis with hyperinflated
lungs and hypoxemia [3]. Children in the first months of
life, particularly those with preterm birth, underlying
chronic lung disease (CLD), congenital heart disease
(CHD), neuromuscular disease, airway malformations or
impaired cellular immunity are at risk for severe disease
[4-6].
Local epidemiological studies are important when consid-
ering new strategies for the prevention of RSV bronchioli-
tis. An example of such a strategy is the monthly injection
of the humanised murine monoclonal antibody palivizu-
mab to certain high-risk groups, which in many studies
has shown a significant reduction in the incidence of hos-
pitalisation for RSV bronchiolitis [7].
The aims of the present study are to identify risk groups,
outcome and incidences of hospitalisation for RSV bron-
chiolitis in Norwegian children under two years of age,
and to compare these results with other studies.
Methods
Background population
Akershus is a large suburban and countryside region
located around the capital of Oslo with approximately
10% of the total population in Norway. The Paediatric
Department at Akershus University Hospital (Ahus) is the
only hospital for children under 15 years of age living in
the 20 northern, southern and eastern communities of the
region and serves all kinds of hospital services, except for
paediatric surgery. Deliveries have been rather stable at
approximately 3.500 per year in the service area during
the last decade. Due to a local agreement infants from
approximately 500 unselected term deliveries from our
service area are born at Rikshospitalet in Oslo each year,
but these infants are admitted to our hospital in case of
disease during childhood. The number of children under
two years of age living in the service area at any time dur-
ing the follow-up period were identified from official Nor-
wegian Population Statistics http://www.ssb.no. The
number of children under two years of age born before
completed 37 weeks of gestation in the service area during
the study period and still alive after the neonatal period
was identified from the Norwegian Medical Birth Registry
http://www.uib.no/mfr. All children with trisomy 21 have
a program for follow-up from birth in our hospital and
the number of children under two years of age with tri-
somy 21 was therefore identified from in-patient and out-
patient hospital records. The number of children in the
general population with a CHD was not known in the
present study and hospitalisation incidences could there-
fore not be estimated. Overall mortality after the neonatal
period as well as the number of children moving out of
the service area during the study period were low and have
not been corrected for.
Study population
The present study is a population-based retrospective sur-
vey on children under two years of age admitted to the
hospital with a diagnosis of bronchiolitis (ICD 9 & 10)
during the period February 5th 1993 to January 31th 2000
and diagnosed as positive with RSV in nasopharyngeal
aspirate (NPA). RSV was diagnosed by an enzyme-linked
immunosorbent assay (ELISA) for RSV (Abbott TestPack
RSV). The test is simple and easy to perform giving a result
within 30 minutes. The sensitivity, specificity, positive
and negative predictive value is stated to be 74–92%, 86–
100%, 81% and 93% respectively [8,9].
764 children who fulfilled the diagnostic criteria were
identified. A total of 77 children belonged to one or more
well known high-risk groups. Of these, 58 children had
been born before completed 37 weeks of gestation, some
with additional diseases such as CLD (12 children) and
CHD (four children). 12 children had a diagnosis of CHD
as the only additional disease and seven children had tri-
somy 21, four of these also diagnosed with CHD. These
77 children were regarded as a high-risk group for sub-
group analysis. No children with other well-known risk-
factors (neuromuscular disease, airway malformations,
impaired cellular immunity or others) were identified.
The remaining 687 children were born at term and
healthy and regarded as a low-risk group for subgroup
analysis.
Statistics
Data were analysed with the statistical programme SPSS,
version 11. For analysis of gender we used the Chi square
test and for comparisons between low-risk and high-risk
groups we used the independent sample T-test. A p-value
<0.05 was used as limit for statistical significance.
Results
Epidemiology
During this seven years follow-up period 764 children
(822 admissions) were hospitalised for RSV bronchiolitis.
93% (707 children) had only one hospitalisation and 7%
(57 children) had two or more hospitalisations for RSV
bronchiolitis during the first two years of life. The highest
number of admissions was recorded during the winter
months December-April, but cases were also found in late
spring and early autumn. Both the number of admissions
and peak-time varied between seasons but with no spe-
cific pattern of variability (figure 1). A significant male
predominance was observed, with 517 (63%) of all
admissions being boys (P < 0.001)Page 2 of 7
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hospitalised within the first year of life with children less
than six months old being responsible for 45% of all
admissions. Median age at hospitalisation was 6 months
(range 0–23 months) and a median length of stay of 4
days (range 1–41 days) was observed (table 1).
During the study period nine children (1.2%) developed
severe respiratory distress and needed mechanical ventila-
tion and two of them (0.3%) died. Four of these children
had no known risk-factors for severe disease. However,
the two children who died were both considered as high-
risk patients, one of them was diagnosed with CHD and
the other with trisomy 21 as well as CHD.
Of all RSV hospitalisations during the first two years of life
58 children (64 admissions) were born before completed
37 weeks of gestation with a median gestational age of 30
weeks (range 24–36 weeks). A significant male predomi-
nance of 68% was also observed in this group (P = 0.006).
Median age on admission, after postnatal age, was 8
months (range 0–23 months). When corrected for prema-
turity (corrected age), median age on admission was 5.4
months (range -2.5–21.3 months). Also, a median length
of hospitalisation of 8 days (range 2–27 days) was
observed (table 1). Two of the preterm children (3.4%)
needed mechanical ventilation and two were treated with
inhaled nebulized ribavirin [10]. No preterm children in
this study died from RSV bronchiolitis.
Seasonal variations in RSV hospitalisationsFigure 1
Seasonal variations by month and year in hospitalisations for RSV bronchiolitis in children under two years of age in Akershus, 
Norway, February 1993 to January 2000
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somy 21 were hospitalised for RSV bronchiolitis during
this follow-up study. Four of them also had a CHD. Two
children needed mechanical ventilation during hospitali-
sation and one of them subsequently died.
A median age on admission of 9.0 months (range 1–20
months) and a median stay of 7.5 days (range 2–34 days)
were recorded for children in this particular risk group
(table 1).
A total of 20 children had a CHD, four combined with
prematurity, four combined with trisomy 21, and 12 with
no other additional risk-factor for severe disease. In the
group of children with only CHD as risk factor median age
on admission was 7.0 months (range 0–23 months) and
median stay of 6.0 days (range 2–14 days) was observed
(table 1). One child needed mechanical ventilation and
subsequently died.
Hospitalisation incidences
Overall hospitalisation incidences were calculated from
the known number by official Norwegian statistics of
58.179 children under two years of age living in the serv-
ice area for the whole study period as well as for each year
as given in table 2. As shown, the overall incidences for
Table 1: Age on admission and length of stay in children under two years of age hospitalised for RSV bronchiolitis in Akershus, Norway, 
February 1993 through January 2000
Risk groups Children (no.) Adm (no.) Median agea P-value (age) Median stayb P-value (stay)
All children 764 822 6.0 4.0
Prematurec 58 64 8.0 NSe 8.0 <0.001e
Corrected aged 58 64 5.4 NSe
Trisomy 21 7 8 9.0 NSe 7.5 <0.001e
CHD* 12 13 7.0 NSe 6.0 NSe
All low-risk 687 737 6.0 4.0
All high-risk 77 85 8.0 0.045e 8.0 <0.001e
Corrected aged 77 85 5.5 NSe
aAge in months
bDays including admission day
cBorn at <37 weeks of gestational age
dCorrected for weeks of prematurity
eVersus low-risk children
Table 2: Mean annual hospitalisation incidences per 1.000 children by age and risk-groups in children under two years of age with RSV 
bronchiolitis in Akershus, Norway, 1993–2000
Children <1 year Children 1–2 years Children 0–2 years
Yeara Popd Adm Inc Popd Adm Inc Popd Adm Inc
All 93–94 4.027 70 17.4 4.195 16 3.8 8.222 86 10.5
All 94–95 3.999 53 13.3 4.192 25 6.0 8.191 78 9.5
All 95–96 3.994 112 28.0 4.132 30 7.3 8.126 142 17.5
All 96–97 4.055 80 19.7 4.143 22 5.3 8.198 102 12.4
All 97–98 4.154 115 27.7 4.242 57 13.4 8.396 172 20.5
All 98–99 4.178 70 16.8 4.350 15 3.4 8.528 85 10.0
All 99–00 4.127 120 29.1 4.391 37 8.4 8.518 157 18.4
All 93–2000 28.534 620 21.7 29.645 202 6.8 58.179 822 14.1
Prematureb 93–2000 1.999c 47 23.5 1.955c 17 8.7 3.954c 64 16.2
Trisomy 21 93–2000 52 8 153.8
aStudy period February 5th, 1993 to January 31th, 2000
bBorn at <37 weeks of gestational age
cNumber of children born at <37 weeks of gestation and corrected for a mean infant mortality rate of 2.4% during the neonatal period
dBackground population for selected risk groupsPage 4 of 7
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1.000 children under one year of age, 6.8 admissions per
1.000 children 1–2 years of age and 14.1 admissions per
1.000 children under two years of age, with some year to
year variation (table 2).
Data from the Norwegian Birth Registry identified that
1.999 infants born in the service area before completed 37
weeks of gestation were alive and below 1 year of age, and
1.955 infants were alive and between 1–2 years of age dur-
ing the study period. As shown, the corresponding hospi-
talisation incidences for preterm children were 23.5, 8.7
and 16.2 per 1.000 children under one year of age, 1–2
years of age and <2 years of age respectively (table 2).
From the hospital records 52 children under two years of
age were diagnosed with trisomy 21 during the follow-up
period. Among these seven children (eight admissions)
were hospitalised for RSV bronchiolitis, giving a hospital-
isation incidence under two years of 153.8 per 1.000
children.
Discussion
In this retrospective study, as in many other comparable
epidemiological studies, we found that RSV bronchiolitis
appears as an annual winter epidemic with relatively high
hospitalisation incidences, predominance of boys, young
age, short length of stay, few complications and low mor-
tality [1]. The rather long study period makes the results
less vulnerable for yearly variations in magnitude of the
annual epidemic and in virulence of the microbe. By using
NPA for microbiological diagnosis in all children with
symptoms of a lower respiratory tract infection like tach-
ypnoe, wheezing or apnoic spells we believe that the great
majority of cases are included. However, the enzyme-
linked immunosorbent assay used in the present study
could give both false positive and false negative results
[9,11].
Several international studies have shown an increased
incidence of RSV-related hospitalisations over the last two
decades. A Norwegian study for the period 1972–78
showed a mean hospitalisation incidence of 9.5 per 1.000
children for children under one year of age compared to
our much higher incidence of 21.7 per 1.000 children for
the period 1993–2000 in the same age group [12]. Also,
for children 1–2 years old the incidence in our study was
much higher. A large study from USA for the period 1980–
96 showed an increased incidence rising from 12.9 per
1.000 children in 1980 to 31.2 per 1.000 children in 1996
for children under one year of age [13]. However, compar-
ing historical data is difficult, and for the period 1993–
2000 we observed no increase in the mean annual hospi-
talisation incidences of RSV bronchiolitis. Factors such as
increased microbial virulence, increased day-care attend-
ance, improved microbiological diagnosis and more pre-
cise ICD-coding might all be important factors to explain
these historical differences. Number of hospitalisations
are also related to the severity of the clinical symptoms.
Thus, changes in hospital admission policies over time as
well as changes in availability of hospital services might
also influence hospitalisation incidences. A recent study
from USA for the period 1997–99 showed that RSV bron-
chiolitis was the leading cause of hospital admissions of
infants younger than one year of age with an associated
hospitalisation incidence of 25.2 per 1.000 infants. This is
in accordance with our findings [14].
Our study showed that only 1.2% of the children in the
study population needed mechanical ventilation. This
result is lower than in many other studies [15]. On the
other hand, when children were in need of mechanical
ventilation, the risk of severe outcome was in our study
very high, with two out of nine mechanically ventilated
children subsequently dying. A Danish study showed that
only 0.6% of their children needed mechanical ventila-
tion, however, 20% of all children with severe respiratory
failure were given ventilatory support with nasal continu-
ous positive airway pressure (N-CPAP) and some infants
possibly avoided mechanical ventilation for that reason
[16]. More controlled studies on different treatment strat-
egies are very much needed, especially when considering
how to avoid respiratory failure and mechanical ventila-
tion [17,18].
Another observation in our study was that among the
mechanically ventilated children 44% had no underlying
risk-factors for severe disease. Further research into why
some otherwise healthy children have a severe course of
RSV bronchiolitis is therefore very important, not least
when trying to define risk groups even better [19].
Research for a better understanding of the host immune
response to RSV bronchiolitis the later years might be one
important piece in this puzzle [20-22].
For the population at large our study showed, as in other
studies, a low mortality. A total of two children (0.3%)
died, one had trisomy 21 with an atrioventricular septum
defect (AVSD) and the other had an underlying CHD.
The number of high-risk children in our study is relatively
small and the results should be interpreted with caution.
The mean hospitalisation incidences for preterm children
were lower than in many other studies, even though 20%
of the preterm children suffered from CLD as well and had
a low median weeks of gestational age (wGA) of 30. One
possible explanation is that the population data for this
particular risk group was not corrected for migration out
of our service area and mortality after the neonatal period.
However, it is unlikely that such corrections would signif-Page 5 of 7
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low incidence among preterm infants might be that most
of them are hospitalised up to almost 40 wGA and are dis-
charged only when the child has reached a weight of more
than 2.000 g and have normal oral feedings. This means
that they are more or less completely protected from RSV
for a long period after birth. Our routines with focus on
good parental information on how to protect the new-
born infant from RSV after discharge from hospital might
also be important. Median length of hospitalisation for
preterm children was in our study significantly longer
when compared to the low-risk children and is in accord-
ance with results from many other larger studies.
Children with CHD are a wellknown risk-group for severe
RSV disease. Children with trisomy 21 with or without a
concomitant CHD should also be considered a high-risk
group. Our study showed a mean hospitalisation inci-
dence per 1.000 children under two years of age with tri-
somy 21 more than 11 times the whole study population.
Even more important, out of a total of seven children with
trisomy 21, two needed mechanical ventilation and one
child died. We would, however, recommend a larger study
to meet these observations for children with trisomy 21.
One of the findings in our study was the large proportion
of otherwise healthy children needing mechanical ventila-
tion. Our numbers are small, but when new policies to
prevent severe RSV bronchiolitis are discussed this aspect
should also be considered. The research for improved
identification of risk-groups and development of an effec-
tive vaccine for immunization should therefore be given
high priority.
Conclusions
While the overall hospitalisation incidences and outcome
of RSV bronchiolitis were in agreement with other studies,
hospitalisation incidences for preterm children were
lower than in many other studies. Age on admission for
preterm children, when corrected for prematurity, was
comparable to low-risk children. Length of hospitalisa-
tion and morbidity was high in both preterm children,
children with a congenital heart disease and in children
with trisomy 21, the last group being at particular high
risk for severe disease.
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
Our individual contributions to the study have been as
following: HOF had primary responsibility for protocol
development, outcome assessment, data acquisition and
analysis and writing of the manuscript. TF participated in
the development of the protocol and analytic framework
of the study, and contributed to the writing of the manu-
script. DB participated in the data analyses and the writing
of the manuscript. All authors read and approved the final
manuscript.
References
1. Law BJ, Carbonell-Estrany X, Simoes EA: An update on respira-
tory syncytial virus epidemiology: a developed country
perspective. Respiratory Medicine 2002, 96 Suppl B:S1-7.
2. Henderson FW, Collier AM, Clyde WAJ, Denny FW: Respiratory-
syncytial-virus infections, reinfections and immunity. A pro-
spective, longitudinal study in young children. N Engl J Med
1979, 300:530-534.
3. Constantopoulos AG, Kafetzis DA, Syrogiannopoulos GA, Roilides EJ,
Malaka-Zafiriu EE, Sbyrakis SS, Marcopoulos ML: Burden of respira-
tory syncytial viral infections on paediatric hospitals: a two-
year prospective epidemiological study. Eur J Clin Microbiol Infect
Dis 2002, 21:102-107.
4. Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB: Impact
of respiratory virus infections on persons with chronic
underlying conditions. Jama 2000, 283:499-505.
5. Fixler DE: Respiratory syncytial virus infection in children with
congenital heart disease: a review. Pediatr Cardiol 1996,
17:163-168.
6. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM:
Respiratory syncytial virus and premature infants born at 32
weeks' gestation or earlier: hospitalization and economic
implications of prophylaxis. Arch Pediatr Adolesc Med 2000,
154:55-61.
7. Simoes EA, Groothuis JR: Respiratory syncytial virus prophy-
laxis--the story so far. Respir Med 2002, 96 Suppl B:S15-24.
8. Wren CG, Bate BJ, Masters HB, Lauer BA: Detection of respira-
tory syncytial virus antigen in nasal washings by Abbott Test-
Pack enzyme immunoassay. J Clin Microbiol 1990, 28:1395-1397.
9. Abels S, Nadal D, Stroehle A, Bossart W: Reliable detection of
respiratory syncytial virus infection in children for adequate
hospital infection control management. J Clin Microbiol 2001,
39:3135-3139.
10. Randolph AG, Wang EE: Ribavirin for respiratory syncytial virus
lower respiratory tract infection. A systematic overview.
Arch Pediatr Adolesc Med 1996, 150:942-947.
11. Holter E, Abrahamsen TG, Rod G, Holten E: Discrepancy between
results of a commercial enzyme immunoassay kit and
immunofluorescence staining for detection of respiratory
syncytial virus antigen. Eur J Clin Microbiol Infect Dis 1998,
17:595-596.
12. Orstavik I, Carlsen KH, Halvorsen K: Respiratory syncytial virus
infections in Oslo 1972--1978. I. Virological and epidemiolog-
ical studies. Acta Paediatr Scand 1980, 69:717-722.
13. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ:
Bronchiolitis-associated hospitalizations among US children,
1980-1996. Jama 1999, 282:1440-1446.
14. Leader S, Kohlhase K: Respiratory syncytial virus-coded pediat-
ric hospitalizations, 1997 to 1999. Pediatr Infect Dis J 2002,
21:629-632.
15. Wang EE, Law BJ, Boucher FD, Stephens D, Robinson JL, Dobson S,
Langley JM, McDonald J, MacDonald NE, Mitchell I: Pediatric Inves-
tigators Collaborative Network on Infections in Canada
(PICNIC) study of admission and management variation in
patients hospitalized with respiratory syncytial viral lower
respiratory tract infection. J Pediatr 1996, 129:390-395.
16. Kristensen K, Dahm T, Frederiksen PS, Ibsen J, Iyore E, Jensen AM,
Kjaer BB, Olofsson K, Pedersen P, Poulsen S: Epidemiology of res-
piratory syncytial virus infection requiring hospitalization in
East Denmark. Pediatr Infect Dis J 1998, 17:996-1000.
17. Krilov LR: Respiratory Syncytial Virus: Update on Infection,
Treatment, and Prevention. Curr Infect Dis Rep 2001, 3:242-246.
18. Kimpen JL: Management of respiratory syncytial virus
infection. Curr Opin Infect Dis 2001, 14:323-328.
19. Nielsen HE, Siersma V, Andersen S, Gahrn-Hansen B, Mordhorst CH,
Norgaard-Pedersen B, Roder B, Sorensen TL, Temme R, Vestergaard
BF: Respiratory syncytial virus infection--risk factors for hos-Page 6 of 7
(page number not for citation purposes)
BMC Pediatrics 2004, 4:25 http://www.biomedcentral.com/1471-2431/4/25Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
pital admission: a case-control study. Acta Paediatr 2003,
92:1314-1321.
20. Bont L, Heijnen CJ, Kavelaars A, van Aalderen WM, Brus F, Draaisma
JM, Pekelharing-Berghuis M, van Diemen-Steenvoorde RA, Kimpen JL:
Local interferon-gamma levels during respiratory syncytial
virus lower respiratory tract infection are associated with
disease severity. J Infect Dis 2001, 184:355-358.
21. Hull J, Thomson A, Kwiatkowski D: Association of respiratory
syncytial virus bronchiolitis with the interleukin 8 gene
region in UK families. Thorax 2000, 55:1023-1027.
22. Piedimonte G: The association between respiratory syncytial
virus infection and reactive airway disease. Respir Med 2002, 96
Suppl B:S25-9.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2431/4/25/prepubPage 7 of 7
(page number not for citation purposes)
